CLEARPOINT NEURO INC (CLPT)
US18507C1036 - Common Stock
CLPT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Health Care Equipment & Supplies industry. CLPT has a bad profitability rating. Also its financial health evaluation is rather negative. CLPT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CLPT has reported negative net income.
In the past year CLPT has reported a negative cash flow from operations.
CLPT had negative earnings in each of the past 5 years.
In the past 5 years CLPT always reported negative operating cash flow.
1.2 Ratios
CLPT's Return On Assets of -51.78% is on the low side compared to the rest of the industry. CLPT is outperformed by 68.75% of its industry peers.
The Return On Equity of CLPT (-104.33%) is worse than 71.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -51.78% | ||
| ROE | -104.33% | ||
| ROIC | N/A |
ROA(3y)-34.46%
ROA(5y)-34.56%
ROE(3y)-59.48%
ROE(5y)-116.8%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CLPT's Gross Margin of 56.84% is in line compared to the rest of the industry. CLPT outperforms 53.65% of its industry peers.
In the last couple of years the Gross Margin of CLPT has declined.
The Profit Margin and Operating Margin are not available for CLPT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.84% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.19%
GM growth 5Y-3.22%
2. Health
2.1 Basic Checks
CLPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLPT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CLPT has been increased compared to 5 years ago.
The debt/assets ratio for CLPT is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -1.59, we must say that CLPT is in the distress zone and has some risk of bankruptcy.
CLPT's Altman-Z score of -1.59 is on the low side compared to the rest of the industry. CLPT is outperformed by 62.50% of its industry peers.
A Debt/Equity ratio of 0.47 indicates that CLPT is not too dependend on debt financing.
CLPT's Debt to Equity ratio of 0.47 is on the low side compared to the rest of the industry. CLPT is outperformed by 61.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.59 |
ROIC/WACCN/A
WACC9.98%
2.3 Liquidity
A Current Ratio of 4.87 indicates that CLPT has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.87, CLPT is doing good in the industry, outperforming 68.23% of the companies in the same industry.
A Quick Ratio of 3.80 indicates that CLPT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.80, CLPT is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.87 | ||
| Quick Ratio | 3.8 |
3. Growth
3.1 Past
CLPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.82%.
Looking at the last year, CLPT shows a quite strong growth in Revenue. The Revenue has grown by 16.55% in the last year.
CLPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 26.65% yearly.
EPS 1Y (TTM)-33.82%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-5.56%
Revenue 1Y (TTM)16.55%
Revenue growth 3Y23.14%
Revenue growth 5Y26.65%
Revenue growth Q2Q31.72%
3.2 Future
The Earnings Per Share is expected to grow by 8.33% on average over the next years. This is quite good.
The Revenue is expected to grow by 34.60% on average over the next years. This is a very strong growth
EPS Next Y15.19%
EPS Next 2Y9.9%
EPS Next 3Y8.33%
EPS Next 5YN/A
Revenue Next Year27.67%
Revenue Next 2Y34.33%
Revenue Next 3Y34.6%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CLPT. In the last year negative earnings were reported.
Also next year CLPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.9%
EPS Next 3Y8.33%
5. Dividend
5.1 Amount
CLPT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CLEARPOINT NEURO INC
NASDAQ:CLPT (5/3/2024, 7:00:00 PM)
After market: 5.94 +0.07 (+1.19%)5.87
+0.35 (+6.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap158.90M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -51.78% | ||
| ROE | -104.33% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.84% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.87 | ||
| Quick Ratio | 3.8 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-33.82%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y15.19%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)16.55%
Revenue growth 3Y23.14%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y